Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.

Detailed Description
-----------------
To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2071 and AD-2072.

Official Title
-----------------
An Open-label, Two-period, One-sequence, Multiple Dosing Crossover Clinical Trial to Evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in Healthy Male Volunteers

Conditions
-----------------
Hyperlipidemias, Hypertension

Intervention / Treatment
-----------------
* Drug: AD-2071 10/20mg
* Drug: AD-2072 80/5mg
* Drug: AD-2071 10/20mg + AD2072 80/5mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male between 19 and 50 years of age at the time of screening Weight between 50 kg and 90 kg and body mass index (BMI) between 18.0 kg/m2 and 27.0 kg/m2 Exclusion Criteria: Clinically significant disease or history of clinically significant disease such as liver, kidney, nervous system, respiratory, endocrine*hematologic, cardiovascular, urinary, psychiatric Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery HDL values less than 35 mg/dL AST, ALT values over than 1.5 times of ULN at screening A person who has a history of drug abuse or who has positive result for an abuse drug in a urine screening test

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence 1<br>Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD | Drug: AD-2071 10/20mg<br>* AD-2071 10/20 mg tablet<br>Drug: AD-2072 80/5mg<br>* AD-2072 80/5mg tablet<br>Drug: AD-2071 10/20mg + AD2072 80/5mg<br>* AD-2071 10/20 mg + AD-2072 80/5mg tablet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak Plasma Concentration | Cmax of the total ingredient of AD-2071 and AD-2072 | pre-dose to 24 hours | 
| Area under the plasma concentration versus time curve | AUCtau of the total ingredient of AD-2071 and AD-20172 | pre-dose to 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to reach Cmax | Tmax of the total ingredient of AD-2071 and AD-2072 | pre-dose to 24 hours | 
| Elimination half-life | t1/2 of the total ingredient of AD-2071 and AD-2072 | pre-dose to 24 hours | 
| Clearance | CL/F of the total ingredient of AD-2071 and AD-2072 | pre-dose to 24 hours | 
| Volume of distribution | Vd/F of the total ingredient of AD-2071 and AD-2072 | pre-dose to 24 hours | 
| Number of participants with adverse events | Incidence rate of adverse events | From Day 1 up to Day 46 |